摘要:
Xanthine derivatives of formula ##STR1## wherein R.sub.1 is hydrogen, alkyl or alkynyl, R.sub.2 is different and is alkyl, alkynyl, phenyl-alkylene, phenyl alkenylene, cycloalkyl, inter alia, R.sub.3 is cycloalkyl, phenyl, norbornane, inter alia and R.sub.4 is hydrogen, methyl, benzyl, inter alia.
摘要:
New imidazotriazolopyrimidine derivatives of the formula Preferred are those compounds wherein: R1 denotes methyl, which is optionally substituted by phenyloxy or pyrrole; or R1 denotes benzyl which is optionally substituted by hydroxy, methoxy, dimethylaminoethoxy or fluorine; or R1 denotes cyclopentyl, furan or phenylethyl; R2 or R3 denote ethyl, n-propyl, allyl or propargyl; R4 or R6 denote hydrogen; and, R5 denotes methyl, n-propyl, tert.butyl, cyclopentyl or norbornenyl. These are adenosine antagonists are are useful for, inter alia, the treatment of senile dementia of the Alzheimer's type.
摘要翻译:式的新咪唑并三唑并嘧啶衍生物优选的是其中:R 1表示甲基,其任选被苯氧基或吡咯取代; 或R 1表示任选被羟基,甲氧基,二甲基氨基乙氧基或氟取代的苄基; 或R 1表示环戊基,呋喃或苯乙基; R 2或R 3表示乙基,正丙基,烯丙基或炔丙基; R 4或R 6表示氢; R5表示甲基,正丙基,叔丁基,环戊基或降冰片烯基。这些腺苷拮抗剂尤其可用于治疗老年痴呆症的老年痴呆症。
摘要:
The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake.
摘要:
The present invention relates to new 4,5,7,8-tetrahydro-6H-thiazolo[5,4-d]azepines of general formula II ##STR1## wherein the substituents are defined herein below, which compounds have valuable pharmacological properties, namely selective effects on the dopaminergic system which are achieved by stimulating (predominantly D2) dopamine receptors.
摘要:
Accordingly, the invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and at least one NMDA receptor antagonists or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
摘要:
This invention relates to new tetrahydrobenzthiazoles of general formula ##STR1## wherein R.sub.1 represents a hydrogen atom, an alkyl group, an alkenyl or alkynyl group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the above mentioned phenyl nuclei may each be substituted by 1 or 2 halogen atoms.R.sub.2 represents a hydrogen atom or an alkyl group,R.sub.3 represents a hydrogen atom, an alkyl group a cycloalkyl group, an alkenyl or alkynyl group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the phenyl nucleus may be substituted by fluorine, chlorine or bromine atoms,R.sub.4 represents a hydrogen atom, an alkyl group, an alkyl or alkenyl group, orR.sub.3 and R.sub.4 together with the nitrogen atom between them represent a pyrrolidino, piperidino, hexamethyleneimino or morpholino group, the enantiomers and the acid addition salts thereof.The compounds of general formula I above in which one of the groups R.sub.1 or R.sub.3 or both groups R.sub.1 and R.sub.3 represent an acyl group are valuable intermediate products for preparing the other compounds of general formula I which have valuable pharmacological properties. The new compounds may be prepared using methods known per se.
摘要:
The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake.